High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results

Acta Oncologica

Volumn 44, Issue 4, 2005, Pages 406-411

  Comandone, Alessandro ^a   Passera, Roberto ^b,d   Boglione, Antonella ^a   Tagini, Valentina ^b   Ferrari, Stefano ^c   Cattel, Luigi ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d Dipartimento di Scienza e Tecnologia del Farmaco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; MALE; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AREA UNDER CURVE; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE;

EID: 22544437840     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029770     Document Type: Article

References (20)

1. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
2. Bertino JR. Clinical use of methotrexate with emphasis on use of high doses. Cancer Treat Rep 1981;65(Suppl 1):131-5.
3. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12:1443-51.
4. Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G. High dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1997;61:779-83.
5. Ferrari S, Sassoli V, Orlandi M, Strazzari S, Puggioli C, Battistini A, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993;5:135-41.
6. Djerassi I, Farber S, Abir E, Neikirk W. Continuous infusion of methotrexate in children with acute leukemia. Cancer 1967;20:233-42.
7. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-31.
8. Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ Jr, et al. High dose methotrexate with citrovorum factor rescue and adriamicyn in childhood osteogenic sarcoma. Cancer 1974;33:1151-63.
9. rd, Jaffe N, Tattersall MH, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975;292:846-51.
10. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histological response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin and cisplatin. J Clin Oncol 1998;16:658-63.
11. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988;42:257-62.
12. Gorlick R, Meyers P, Kellick M, Bertino JR. Monitoring methotrexate levels in osteosarcoma. J Clin Oncol 1998;16:2290-1.
13. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994;33:420-4.
14. Raude E, Oellerich M, Weinel P, Freund M, Schrappe M, Riehm H, et al. High dose methotrexate: pharmacokinetics in children and young adults. Intl J Clin Pharmacol Ther Toxicol 1988;26:364-70.
15. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to IOR/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27.
16. Shargel L, Yu A. Applied biopharmaceutics & pharmacokinetics. Appleton & Lange, New York 1999.
17. Food and Drug Administration. Guidance for Industry Population Pharmacokinetic. U.S. Dept. of Health, Rockville 1999.
18. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-8.
19. Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachatre G, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet 2002;41:1095-104.
20. Jaffe N, Link MP, Cohen D, Traggis D, Frei E 3rd, Watts H, et al. High dose methotrexate in osteogenic sarcoma. NCI Monogr 1981;56:201-6.